Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193360 | SCV001362123 | uncertain significance | not specified | 2019-12-17 | criteria provided, single submitter | clinical testing | Variant summary: BRCA2 c.10061delC (p.Ser3354LeufsX29) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant is located downstream of a well-known polymorphism c.9976A>T (p.Lys3326X), that results in a truncated protein, suggesting that the region of the BRCA2 gene beyond codon 3326 is not crucial for proper function. The variant was absent in 251146 control chromosomes (gnomAD). To our knowledge, no occurrence of c.10061delC in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Labcorp Genetics |
RCV002560164 | SCV002961418 | likely benign | Hereditary breast ovarian cancer syndrome | 2022-09-26 | criteria provided, single submitter | clinical testing | |
Laboratory for Genotyping Development, |
RCV003163488 | SCV002758341 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |